๐ฌ Current Disease Focus:
Task Progress: 0%
๐ฅ Active Problem Solvers
0
๐ Experts collaborating globally
โก Current Task Assignment
๐งฌ Genetic Analysis
๐ Matching experts to specific tasks
๐ Resource Allocation by Research Phase:
๐ Data Analysis
๐งช Experimental Design
๐ฌ Clinical Trials
๐ Treatment Development
The purpose of the study is to evaluate the efficacy of the triplet of rida...
Status
Completed
Location
Multiple Locations
Start Date
2012-07-04
Trial ID
NCT01605396
Treatments Being Tested
This study will look for the highest tolerated dose of dalotuzumab (MK-0646...
Status
Completed
Location
Multiple Locations
Start Date
2006-01-12
Trial ID
NCT00701103
Treatments Being Tested
The goals of this clinical research study are to learn the tolerable and ef...
Status
Terminated
Location
UT MD Anderson Cancer Center
Start Date
2009-11
Trial ID
NCT00903006
Treatments Being Tested
RATIONALE: Monoclonal antibodies, such as MK-0646, can block tumor growth i...
Status
Completed
Location
Juravinski Cancer Centre at Hamilton Health Sciences
Start Date
2009-12-16
Trial ID
NCT00869752
Treatments Being Tested
The purposes of this study were to assess the safety, tolerability, pharmac...
Status
Completed
Location
Multiple Locations
Start Date
2009-06-17
Trial ID
NCT00925015
Treatments Being Tested
The purpose of this study is to test a new drug for neuroendocrine tumors. ...
Status
Completed
Location
Memorial Sloan-Kettering at Basking Ridge
Start Date
2008-01
Trial ID
NCT00610129
Treatments Being Tested
This is a Phase I/IIa study to evaluate safety and efficacy of dalotuzumab ...
Status
Completed
Location
Multiple Locations
Start Date
2008-03-19
Trial ID
NCT00654420
Treatments Being Tested
This is a two-part study that will determine, if: 1) the combination of rid...
Status
Completed
Location
Multiple Locations
Start Date
2010-09-17
Trial ID
NCT01234857
Treatments Being Tested
This study will use imaging to look at tumor response to erlotinib (Part I)...
Status
Completed
Location
Multiple Locations
Start Date
2009-02
Trial ID
NCT00729742
Treatments Being Tested
Objectives: Primary Objectives: * Phase I: Determine the maximal tolerate...
Status
Completed
Location
University of Texas MD Anderson Cancer Center
Start Date
2008-11-13
Trial ID
NCT00769483
Treatments Being Tested